Kyriakos A. Kirou, MD, DSc, FACP

If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.

Appointments

Affiliations

American College of Rheumatology, Fellow
American College of Physicians, Fellow
Arthritis Foundation Member, Member
Hellenic Medical Society of New York, Member
New York Rheumatism Association, Member
National Psoriasis Foundation, Member

Certification

American Board of Internal Medicine, 1995, 2005, 2015
American Board of Rheumatology, 1998, 2008, 2018

Awards

Best Doctors in America, 2019
America’s Best Physicians. Natl Consumer Advisory Board, 2017
HSS Division of Rheumatology Teaching Excellence Award, 2017
HSS Division of Rheumatology Teaching Excellence Award, 2007 
ACR Annual Slide Competition, Third Place, 2006
NIAID/NIH Mentored Clinical Scientist Development Award (KO8), 2003
ACR/REF Global Arthritis Research Network Travel Grant, 2002
Merck 2000 Rheumatology Young Investigator, 2000
Extended Fellowship Grant Award (3 years), The SLE Foundation Inc., 1999
Fellowship Grant Award, Arthritis Foundation, New York Chapter, 1998 
ACR/REF Travel Award, 1998

Education

MD, Aristotle University of Thessaloniki, Greece
DSc, National University of Athens, Greece

Residency

Internal Medicine, New York Hospital of Queens, Flushing, New York

Fellowship

Rheumatology, Hospital for Special Surgery

State Licensure

Languages

English, Greek

Patient Education

• Relapsing Lupus Nephritis and Cutaneous Vasculitis: A Race to Contain B Cells
• Lupus Nephritis: What You Should Know About Lupus and Kidney Disease
• Managing and Treating Lupus
• Neuropsychiatric Lupus – Lupus and the Brain
• Joint Pain in People with Lupus: Is It Really Arthritis?
• Lupus Research at Hospital for Special Surgery: An Introduction

Professional Education

• Relapsing Lupus Nephritis and Cutaneous Vasculitis: A Race to Contain B Cells

Selected Journal Articles

For all publications, please see the PubMed listing.

Dr. Kyriakos Kirou has been very active in the translational and clinical research of systemic lupus erythematosus (SLE). Our studies, along with those of others, have identified the important role of type I IFN in the pathogenesis of lupus, and have paved the way for better understanding of this disease and the development of new lupus therapeutic targets. We have been part of the Lupus Clinical Investigators Network (LuCIN) and the Lupus Nephritis Trials Network and actively participating in important clinical trials for lupus and lupus nephritis at HSS.

Research Videos

Lupus Nephritis in 2023

What's New in Lupus Research and How to Participate

Clinical Trials / Research Studies

• An Open Label Multicenter Study to Assess the Relationship Between Data Obtained with the LuGENE Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients with Systemic Lupus Erythematosus (SLE)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately To Severely Active Systemic Lupus Erythematosus
• A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-Care Therapy in Participants with Active Lupus Nephritis (SIRIUS-LN)
• A Phase 3 Randomized. Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)
• Systemic Lupus Erythematosus (SLE) Treatment with N-acetylcysteine (NAC) (SNAC)
• Autoimmune Disease Registry and Repository
• A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
• A Novel Phase 2 Double-Blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-Toxic ACE Inhibition in Cognitive Impairment Associated with SLE
• A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
• A Multicentre, Randomized, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterize the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
• Studies of Immune Deregulation in Patients with SLE
• Can Body Composition Help us Better Understand Outcomes in People with Lupus?
• Gleevec in the Treatment of Systemic Sclerosis - EXTENSION STUDY
• Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis: a Randomized, Controlled Phase 2 Open Label Multicenter Study
• Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial
• A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy & Safety of MBS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) & Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis
• A Phase 2B, Dose Ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with SLE
• Scleroderma Cyclophosphamide or Transplantation (SCOT) Study
• Rituximab Therapy For The Induction Of Remission And Tolerance In ANCA-Associated Vasculitis
• A Phase 1 Double Blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI 570 in SLE
• Gleevec in the Treatment of Systemic Sclerosis